Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 25, 2025, covers the results of the Company's Annual Meeting of Stockholders and the subsequent announcement of a reverse stock split. Catheter Precision, Inc. is a Delaware corporation listed on the NYSE American under the ticker symbol VTAK.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and capital structure adjustments.
Material Changes and Corporate Actions
- Reverse Stock Split: The Board of Directors approved a 1-for-19 reverse stock split, effective August 15, 2025. This action is intended to ensure compliance with NYSE American minimum bid price requirements.
- Share Count Reduction: Outstanding common shares will be reduced from approximately 23.3 million to approximately 1.2 million shares. No fractional shares will be issued; they will be settled in cash.
- Stockholder Voting Results: Approximately 46.1% of outstanding shares were represented at the Annual Meeting. All six proposals were approved, including:
- Election of Martin Colombatto as a Class I director.
- Authorization to issue up to 4,285,716 shares upon exercise of Series L Warrants.
- Authorization to issue up to 8,574,000 shares upon conversion of Series B Convertible Preferred Stock.
- Authorization to issue up to 257,143 shares upon exercise of 2025 Placement Agent Warrants.
- Approval of the reverse stock split (1-for-5 to 1-for-19 range).
- Ratification of WithumSmith+Brown, PC as the independent auditor for fiscal year 2025.
Guidance, Outlook, and Risks
Management stated the primary objective of the reverse stock split is to maintain listing compliance on the NYSE American. The Company cautioned that forward-looking statements regarding the split's effectiveness and continued listing status involve risks, including the possibility of de-listing or delays in the split implementation. The filing refers investors to the Form 10-K for the year ended December 31, 2024, for additional risk factors.
Investor Verification Checklist
- Verify the effective date of the reverse stock split (August 15, 2025) and the new CUSIP number (74933X 708).
- Confirm the treatment of fractional shares (cash settlement) and the impact on individual holdings.
- Monitor the post-split trading price to ensure it meets the NYSE American minimum bid price requirement.
- Review the definitive proxy statement (Schedule 14A) filed on June 9, 2025, for detailed rationale on the warrant and preferred stock issuances.
- Check for any subsequent filings regarding the Certificate of Amendment to the Certificate of Incorporation.